You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed/refractory AML

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)

Recruiting
  • AML
  • MDS
  • Tuebingen, Baden-Wuerttemberg, Germany
    University Hospital
Nov 30, 2023

Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

Not yet recruiting
  • Relapsed/Refractory AML
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 28, 2023

AML, Adult Trial in Berne (HDM201, Midostaurin)

Terminated
  • AML, Adult
  • Berne, Switzerland
    Departement of Medical Oncology, University Hospital Berne
Oct 3, 2022

Acute Myeloid Leukemia Trial in Baltimore (Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Dose Escalation -tagraxofusp-erzs
  • Dose Expansion at RP2D -tagraxofusp-erzs
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 27, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, MDS Trial (biological, drug, procedure)

Withdrawn
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Cytokine-induced memory-like NK cells
  • +4 more
  • (no location specified)
Feb 23, 2022

AML, AML, Adult Trial in Indianapolis (TAK-659, Ixazomib)

Terminated
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
Mar 15, 2022

Acute Myeloid Leukemia Trial (MCBC regimen, Bu/Cy regimen)

Not yet recruiting
  • Acute Myeloid Leukemia
  • MCBC regimen
  • Bu/Cy regimen
  • (no location specified)
Nov 13, 2023

Acute Myeloid Leukemia Trial in Columbus (Universal Donor Natural Killer Cells)

Recruiting
  • Acute Myeloid Leukemia
  • Universal Donor Natural Killer Cells
  • Columbus, Ohio
    Nationwide Children's Hospital
Aug 11, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Trial in Zhengzhou (6MW3211

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • 6MW3211 injection with Intravenous Infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 2, 2022

AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)

Not yet recruiting
  • AML/MDS
  • +2 more
  • (no location specified)
Aug 14, 2023

Bortezomib, Acute Myeloid Leukemia Trial in Wuhan (DAG pre-excitation regimen with Bortezomib)

Recruiting
  • Bortezomib
  • Acute Myeloid Leukemia
  • DAG pre-excitation regimen with Bortezomib
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Jul 31, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))

Not yet recruiting
  • AML, Adult
  • Pharmacoscopy
  • Clinical standard-of-care (physician's choice)
  • (no location specified)
Nov 20, 2023

Acute Myeloid Leukemia, in Relapse Trial in Baltimore, Chapel Hill (pembrolizumab,)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia, in Relapse
  • Baltimore, Maryland
  • +1 more
Aug 10, 2022

Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

Recruiting
  • Acute Myeloid Leukemia (Relapsed/Refractory)
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 16, 2023

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)

Not yet recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • (no location specified)
May 24, 2023

AML, Adult Recurrent, MDS Trial in Durham (DVX201)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • DVX201
  • Durham, North Carolina
    Duke University Hospital
Feb 11, 2022

MDS, Acute Myeloid Leukemia Trial in New Haven (AG-120, Nivolumab)

Withdrawn
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • New Haven, Connecticut
    Yale Cancer Center
Jan 6, 2022

Acute Myeloid Leukemia Trial in Cincinnati (CIML-NK Cells)

Recruiting
  • Acute Myeloid Leukemia
  • CIML-NK Cells
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Jan 4, 2023

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)

Not yet recruiting
  • CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
  • +3 more
  • (no location specified)
Nov 14, 2022

Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,

Recruiting
  • Stem Cell Transplant Complications
  • +4 more
  • Radiation
  • +7 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

AML, Childhood Trial in United States (Nivolumab, 5-azacytidine)

Active, not recruiting
  • AML, Childhood
  • Los Angeles, California
  • +11 more
Oct 10, 2022

Relapsed/Refractory AML Trial in United States (CLN-049)

Recruiting
  • Relapsed/Refractory AML
  • Tampa, Florida
  • +3 more
Dec 2, 2021